Minerva Neurosciences Advances Roluperidone Trial with 2027 Data Expected — Minerva Neurosciences, Inc.

Event summary

Minerva's Phase 3 trial for roluperidone in negative schizophrenia symptoms is ongoing, with topline efficacy data expected in the second half of 2027.
The company expanded its Scientific Advisory Board to eleven members, including experts from Hofstra University and Technical University of Munich.
Second-quarter R&D expenses rose to $7.2 million, primarily due to the C19 trial costs.
GAAP net income for Q2 2026 was $17.5 million, driven by a non-cash gain on warrant liability.

The big picture

Minerva is betting heavily on roluperidone as the only late-stage candidate targeting negative symptoms in schizophrenia, a high-need area with limited therapeutic options. The company’s strategic focus on this niche could position it for significant market share if successful, but requires sustained execution through 2028. The expanded Scientific Advisory Board suggests a push toward thought leadership in CNS disorders.

What we're watching

Trial Execution: Whether Minerva can maintain the pace of enrollment and data collection across 40 global sites to meet the 2027 deadline.
Regulatory Pathway: How FDA discussions will shape the final design and approval prospects for roluperidone.
Financial Sustainability: The impact of rising R&D expenses on Minerva's cash runway, given current reserves of $75.4 million.